Clinical trials: Recurrent Small Cell Lung Cancer, open to volunteers
Solid Tumors, Advanced Cancer
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion…
- Conditions
- Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer
- Trial name
- SPARTA (NCT03175224)
- Testing
- APL-101 Oral Capsules
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 497 people
- Sponsor
- Apollomics Inc.
Lung Cancer, Non Small Cell Lung Cancer
Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy
Primary Objective: Evaluate the role of ctDNA positivity in decision making for postoperative therapy for non-small cell lung cancer.
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Lung Cancer Recurrent
- Trial name
- PORT (NCT06979661)
- Testing
- Haystack™ ctDNA Assay
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Rutgers, The State University of New Jersey
Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Testing Repeat Radiation Therapy for Recurrent Non-small Cell Lung Cancer
This phase II trial compares repeat radiation therapy (RT) to standard drug treatment alone in treating patients with stage II-III non-small cell lung cancer (NSCLC) that has come back after initial radiation at or adjacent to…
- Conditions
- Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Trial name
- NCT07835789
- Testing
- Biospecimen Collection, Computed Tomography, Immunotherapy
- Volunteers
- 138 people
- Sponsor
- NRG Oncology
Metastatic Non Small Cell Lung Cancer
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
- Trial name
- NCT04614103
- Testing
- LN-145
- Where
- 71 sites in United States, Australia and 10 more
- Volunteers
- 170 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Small-cell Lung Cancer
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
- Trial name
- DLLEVATE (NCT07218146)
- Testing
- ZL-1310, Investigator's Choice of Therapy
- Where
- 165 sites in United States, Austria and 13 more
- Volunteers
- 480 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Non-small Cell Lung Cancer
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung…
- Trial name
- RELATIVITY1093 (NCT06561386)
- Testing
- Nivolumab, Relatlimab, Pembrolizumab
- Where
- 329 sites in United States, Argentina and 29 more
- Volunteers
- 1,000 people
- Sponsor
- Bristol-Myers Squibb
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma
Q702 for the Treatment of Patients With Hematologic Malignancies
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents.
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06712810
- Testing
- Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Mayo Clinic
Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT04919382
- Testing
- Atezolizumab, Temozolomide
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Dwight Owen
Endometrial Cancer, Ovarian Cancer
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid…
- Conditions
- Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent
- Trial name
- NCT07444814
- Testing
- HWK-007
- Where
- 12 sites in United States
- Volunteers
- 226 people
- Sponsor
- Whitehawk Therapeutics, Inc.
Unresectable Melanoma, Metastatic Melanoma
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT05361174
- Testing
- IOV-4001
- Where
- 11 sites in United States
- Volunteers
- 53 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Small Cell Lung Cancers, Neuroendocrine Carcinoma
The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]
This protocol is a molecular screening protocol only. No drug intervention study will be included in this protocol. Based on the molecular profiling, patients may be eligible for drug intervention study of SUKSES trial.
- Trial name
- NCT02688894
- Testing
- No treatment is included in this protocol.
- Where
- 6 sites in South Korea
- Volunteers
- 797 people
- Sponsor
- Samsung Medical Center
Metastatic Non Small Cell Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma
MOv19-BBz CAR T Cells in FRa+ Cancers
This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers.
- Trial name
- NCT07116057
- Testing
- MOv19-BBz CAR T cells, Cyclophosphamide/Fludarabine, FRa Expression Testing
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Neoplasms, Lung
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread.
- Trial name
- NCT07099898
- Testing
- Risvutatug rezetecan (Ris-Rez), Topotecan
- Where
- 144 sites in United States, Argentina and 23 more
- Volunteers
- 420 people
- Sponsor
- GlaxoSmithKline
Lung Cancer, Relapse/Recurrence
Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
For patients with lung cancer who have undergone tumor resection, early relapse significantly impacts survival. However, there are currently no reliable screening or imaging tools available to identify patients at risk of early…
- Trial name
- NCT06262386
- Testing
- Cisplatin based chemottherapy
- Where
- Taiwan
- Volunteers
- 358 people
- Sponsor
- Chang Gung Memorial Hospital
Non-Small Cell Lung Cancer, Minimal Residual Disease
Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA
This is a multicenter, prospective, observational pilot cohort study in patients with surgically resected non-small cell lung cancer (NSCLC, pathologic stage IA3-IIIA).
- Trial name
- LUNG-MRDetect (NCT07921888)
- Testing
- Patient-specific tumor-informed MRD assay (plasma and bronchial washing ctDNA), Bronchoscopy with bronchial washing for reserach
- Where
- 3 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Eun Hye Lee
Squamous Non-Small Cell Lung Cancer SqNSCLC
Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study
The goal of this single-arm, multi-center phase II clinical study is to evaluate the efficacy and safety of recombinant human endostatin (rh-Endostatin) combined with nab-paclitaxel, platinum-based chemotherapy, and PD-1…
- Trial name
- NCT06747169
- Testing
- Sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin
- Volunteers
- 32 people
- Sponsor
- Jian-Guo Zhou, MD, PhD
Small-cell Lung Cancer
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).
- Trial name
- NCT07189455
- Testing
- ZG006, Topotecan
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
This phase II Expanded Lung-MAP treatment trial compares how well sacituzumab govitecan alone, ivonescimab alone, or sacituzumab govitecan in combination with ivonescimab works in treating patients with non-small cell lung cancer…
- Trial name
- NCT07393555
- Testing
- Biospecimen Collection, Computed Tomography, Ivonescimab
- Where
- 41 sites in United States
- Volunteers
- 117 people
- Sponsor
- SWOG Cancer Research Network